Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome

Experimental and Clinical Endocrinology and Diabetes

Volumn 114, Issue 7, 2006, Pages 371-376

  Heald, A H ^a,b,c   Kaushal, K ^a   Siddals, K W ^a   Rudenski, A S ^a   Anderson, S G ^a   Gibson, J M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BISHOP AUCKLAND GENERAL HOSPITAL   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; IGFBP; Metabolic syndrome; Type 2 diabetes

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; LIPID; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CONTROLLED STUDY; ETHNOLOGY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; C-PEPTIDE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LIPIDS; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 33747589672     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924320     Document Type: Article

References (28)

1. Boni-Schnetzler M, Schmid C, Mary JL, Zimmerli B, Meier PJ, Zapf J, Schwander J, Froesch ER. Insulin regulates the expression of the insulin-like growth factor binding protein 2 mRNA in rat hepatocytes. Molecular Endocrinology 1990; 4: 1320-1326
2. Boulle N, Baudin E, Gicquel C, Logie A, Bertherat J, Penfornis A, Bertagna X, Luton JP, Schlumberger M, Le Bouc Y. Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors. European Journal of Endocrinology 2001; 144: 29-36
3. Clemmons DR. Role of peptide growth factors in development of macrovascular complications of diabetes. Diabetes Care 1991; 14: 153-156
4. Clemmons DR, Snyder DK, Busby WH Jr. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. Journal of Clinical Endocrinology & Metabolism 1991; 73: 727-733
5. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. Journal of Clinical Endocrinology & Metabolism 1993; 76: 1031-1035
6. Conover CA, Lee PD, Kanaley JA, Clarkson JT, Jensen MD. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. Journal of Clinical Endocrinology & Metabolism 1992; 74: 1355-1360
7. Cruickshank JK, Heald AH, Anderson SG, Cade JE, Sampayo J, Riste LK, Greenhalgh A, Taylor W, Fraser W, White A, Gibson JM. Epidemiology of the insulin-like growth factor system in three ethnic groups. American Journal of Epidemiology 2001; 154: 504-513
8. De W, Czernichow P, Asfari M. Discordant regulation of insulin-like growth factor-II and insulin-like growth factor binding protein-2 gene expression in a rat beta-cell line. Growth Regulation 1996; 6: 83-87
9. Ernst CW, White ME. Hormonal regulation of IGF-binding protein-2 expression in proliferating C2C12 myoblasts. Journal of Endocrinology 1996; 149: 417-429
10. Expert Panel on Detection EaToHBCiA. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association 2001; 285: 2486-2497
11. Gibson JM, Westwood M, Crosby SR, Gordon C, Holly JM, Fraser W, Anderson C, White A, Young RJ. Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology & Metabolism 1995; 80: 1369-1375
12. Gibson JM, Westwood M, Young RJ, White A. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). Journal of Clinical Endocrinology & Metabolism 1996; 81: 860-863
13. Coke B, Fehmann HC. Insulin and insulin-like growth factor-1: their role as risk factors in the development of diabetic cardiovascular disease. Diabetes Research & Clinical Practice 1996; 30: 93-106
14. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A, Gibson JM. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001; 44: 333-339
15. Heald AH, Siddals KW, Fraser W, Taylor W, Kaushal K, Morris J, Young RJ, White A, Gibson JM. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes 2002; 51: 2629-2636
16. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I, and IGFBP-1 levels in an elderly population: relation to cardiovascular risk factors and disease. [erratum appears in Arterioscler Thromb Vasc Biol 1998 Jul; 18: 1197] Arterioscler Thromb Vasc Biol 1998; 18: 277-282
17. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor 1 is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002; 10: 939-944
18. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Hormone and IGF Research 2003; 13: 113-170
19. Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J, Karasik A. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. British Journal of Cancer 1996; 73: 1069-1073
20. Leinonen ES, Salonen JT, Salonen RM et al. Reduced IGFBP-I is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care 2002; 25: 1807-1812
21. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. British Journal of Cancer 2000; 83: 1344-1350
22. Renehan AG, Toogood AA, Ryder WD, Jones J, Potten CS, O'Dwyer ST, Shalet SM. Paradoxical elevations in serum IGF-II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides. Clinical Endocrinology 2001; 55: 469-475
23. Rudenski AS, Matthews DR, Levy JC, Turner RC. Understanding "insulin resistance": both glucose resistance and insulin resistance are required to model human diabetes. Metabolism Clinical & Experimental 1991; 40: 908-917
24. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-1 and the development of glucose intolerance: a prospective observational study. Lancet 2002; 359: 1740-1745
25. Schmid C, Schlapfer I, Waldvogel M, Meier PJ, Schwander J, Boni-Schnetzler M, Zapf J, Froesch ER. Differential regulation of insulin-like growth factor binding protein (IGFBP)-2 mRNA in liver and bone cells by insulin and retinoic acid in vitro. FEBS Letters 1992; 303: 205-209
26. Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004; 32: 859-868
27. Turner RC, Rudenski AS, Matthews DR, Levy JC, O'Rahilly SP, Hosker JP. Application of structured model of glucose-insulin relations to assess beta-cell function and insulin sensitivity. Horm Metab Res Supplement 1990; 24: 66-71
28. Vaessen N, Heutink P, Janssen JA, Witteman JCM, Testers L, Hofman A, Lamberts SWJ, Oostra BA, Pols HAP, van Duijn CM. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001; 50: 637-642